METHODS: PubMed, Scopus, and Web of Science were searched until May 2022. Twelve eligible trials were included. The pooled results were reported as weighted mean differences (WMD) and 95 % confidence intervals (CIs). The Cochrane risk of bias and GRADE tools were used to assess the risk of bias and certainty of the evidence, respectively.
RESULTS: Tart cherry generally showed no significant effects on cardiometabolic risk factors. But subgroup analysis revealed that tart cherry significantly lowered total cholesterol (WMD: -0.33 mmol/l; 95 % CI: -0.55, -0.10), triglyceride (WMD: -0.19 mmol/l; 95 % CI: -0.26, -0.12), and low-density lipoprotein cholesterol (WMD: -0.36 mmol/l; 95 % CI: -0.58, -0.14), in unhealthy populations. Additionally, subgroup analysis indicated that the favorable effects of tart cherry were more pronounced in a single dose, longer duration, elderly, and obese individuals. Dose-response analysis revealed that 20 ml concentrate has the greatest effect in reducing total cholesterol (WMD: -0.40 mmol/l; 95 % CI: -0.61, -0.19), triglyceride (WMD: -0.23 mmol/l; 95 % CI: -0.33, -0.13), and elevating high-density lipoprotein cholesterol (WMD: 0.20 mmol/l; 95 % CI: 0.17, 0.22).
CONCLUSIONS: Tart cherry supplementation did not have significant effects on anthropometric and glycemic indices, but can improve lipid profile, especially in a single dose, longer duration, and in elderly, obese, and unhealthy individuals.
方法:PubMed,Scopus,和WebofScience一直搜索到2022年5月。包括12项符合条件的试验。汇总结果报告为加权平均差异(WMD)和95%置信区间(CI)。使用Cochrane偏差风险和GRADE工具来评估偏差风险和证据的确定性,分别。
结果:Tartcherry通常对心脏代谢危险因素没有显着影响。但是亚组分析显示,酸樱桃显着降低总胆固醇(WMD:-0.33mmol/l;95%CI:-0.55,-0.10),甘油三酯(WMD:-0.19mmol/l;95%CI:-0.26,-0.12),和低密度脂蛋白胆固醇(WMD:-0.36mmol/l;95%CI:-0.58,-0.14),在不健康的人群中。此外,亚组分析表明,酸樱桃的有利作用在单剂量更明显,持续时间较长,老年人,和肥胖的人。剂量反应分析表明,20毫升浓缩物在降低总胆固醇方面具有最大的作用(WMD:-0.40mmol/l;95%CI:-0.61,-0.19),甘油三酯(WMD:-0.23mmol/l;95%CI:-0.33,-0.13),并升高高密度脂蛋白胆固醇(WMD:0.20mmol/l;95%CI:0.17,0.22)。
结论:补充Tart樱桃对人体测量和血糖指数没有显著影响,但可以改善血脂状况,尤其是单剂量,持续时间较长,在老年人中,肥胖,不健康的人。